Ronald MD - Arvinas Chief Officer
| ARVN Stock | USD 25.11 2.42 10.67% |
Executive
Ronald MD is Chief Officer of Arvinas
| Age | 58 |
| Address | 5 Science Park, New Haven, CT, United States, 06511 |
| Phone | 203 535 1456 |
| Web | https://www.arvinas.com |
Arvinas Management Efficiency
The company has return on total asset (ROA) of (0.2007) % which means that it has lost $0.2007 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5916) %, meaning that it created substantial loss on money invested by shareholders. Arvinas' management efficiency ratios could be used to measure how well Arvinas manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.3. In addition to that, Return On Capital Employed is likely to drop to -0.4. At this time, Arvinas' Non Currrent Assets Other are very stable compared to the past year. As of the 22nd of November 2024, Fixed Asset Turnover is likely to grow to 5.73, while Total Assets are likely to drop about 753.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Karen Weisbach | Kymera Therapeutics | N/A | |
| Karah JD | Ultragenyx | 46 | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| Jeremy Chadwick | Kymera Therapeutics | 61 | |
| Eric JD | Nurix Therapeutics | 57 | |
| Juliet BA | Kymera Therapeutics | N/A | |
| George Fromm | Shattuck Labs | N/A | |
| Erika Jones | Black Diamond Therapeutics | 39 | |
| Deborah MBA | Relay Therapeutics | N/A | |
| Kathleen Ford | Kura Oncology | 77 | |
| Michael Naso | Century Therapeutics | N/A | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Cristiana Guiducci | Nurix Therapeutics | N/A | |
| Conor CPA | Shattuck Labs | N/A | |
| Michael MD | Century Therapeutics | 53 | |
| Eric MD | Pliant Therapeutics | 60 | |
| Pete Spain | Kura Oncology | N/A | |
| Francis Burrows | Kura Oncology | N/A | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| JD Esq | Kura Oncology | 53 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.2 |
Arvinas Leadership Team
Elected by the shareholders, the Arvinas' board of directors comprises two types of representatives: Arvinas inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arvinas. The board's role is to monitor Arvinas' management team and ensure that shareholders' interests are well served. Arvinas' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arvinas' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Treasurer | ||
| Ian Taylor, Chief Scientific Officer | ||
| Paul McInulty, Senior Affairs | ||
| Matthew JD, Gen Sec | ||
| John Grosso, Senior Operations | ||
| Randy Teel, Senior Development | ||
| John Houston, President CEO, Director | ||
| Ronald MD, Chief Officer | ||
| Steve Weiss, Senior Officer | ||
| Andrew Saik, CFO Treasurer | ||
| Ronald Peck, Chief Medical Officer | ||
| Lisa Sinclair, Senior Operations | ||
| Angela Cacace, Senior Biology | ||
| Jared JD, General Secretary | ||
| John Northcott, Chief Officer | ||
| David MBA, Principal VP | ||
| Jeff Boyle, Vice Relations |
Arvinas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arvinas a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (1.92) % | ||||
| Operating Margin | (0.59) % | ||||
| Current Valuation | 439 M | ||||
| Shares Outstanding | 68.71 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 92.78 % | ||||
| Number Of Shares Shorted | 8.8 M | ||||
| Price To Earning | (0.45) X |
Pair Trading with Arvinas
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arvinas position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arvinas will appreciate offsetting losses from the drop in the long position's value.Moving against Arvinas Stock
The ability to find closely correlated positions to Arvinas could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arvinas when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arvinas - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arvinas to buy it.
The correlation of Arvinas is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arvinas moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arvinas moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arvinas can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arvinas. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Arvinas Stock, please use our How to Invest in Arvinas guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arvinas. If investors know Arvinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arvinas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.79) | Revenue Per Share 2.327 | Quarterly Revenue Growth 1.96 | Return On Assets (0.20) | Return On Equity (0.59) |
The market value of Arvinas is measured differently than its book value, which is the value of Arvinas that is recorded on the company's balance sheet. Investors also form their own opinion of Arvinas' value that differs from its market value or its book value, called intrinsic value, which is Arvinas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arvinas' market value can be influenced by many factors that don't directly affect Arvinas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arvinas' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arvinas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arvinas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.